TipRanks
Go Ultimate55% OFF

Compare 3SBio (83B) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:83B3SBioEUR 1.50EUR 3.92B3.45-49.73%Strong BuyUnlock the DE:83B analyst price target with TipRanks PremiumDE:83BUnlock the DE:83B top-analyst price target with TipRanks Premium
HK:2269Wuxi Biologics (Cayman)HKD 44.48HKD 183.11B31.1321.60%Strong BuyUnlock the HK:2269 analyst price target with TipRanks PremiumDE:83B vs HK:2269Unlock the HK:2269 top-analyst price target with TipRanks Premium
HK:9926Akeso, Inc.HKD 81.50HKD 76.70B-66.36-26.51%Strong BuyUnlock the HK:9926 analyst price target with TipRanks PremiumDE:83B vs HK:9926Unlock the HK:9926 top-analyst price target with TipRanks Premium
HK:9995RemeGen Co. Ltd. Class HHKD 64.85HKD 51.82B7.89-23.25%Strong BuyUnlock the HK:9995 analyst price target with TipRanks PremiumDE:83B vs HK:9995Unlock the HK:9995 top-analyst price target with TipRanks Premium
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class HHKD 15.26HKD 30.07B-69.15-39.11%Moderate BuyUnlock the HK:1877 analyst price target with TipRanks PremiumDE:83B vs HK:1877Unlock the HK:1877 top-analyst price target with TipRanks Premium
HK:2696Shanghai Henlius Biotech, Inc. Class HHKD 49.06HKD 26.75B26.13-25.78%Strong BuyUnlock the HK:2696 analyst price target with TipRanks PremiumDE:83B vs HK:2696Unlock the HK:2696 top-analyst price target with TipRanks Premium

Performance Comparison

-75%-50%-25%0%25%50%75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:83B3SBio1.50-1.96-56.71%
HK:2269Wuxi Biologics (Cayman)44.488.8624.87%
HK:9926Akeso, Inc.81.50-36.80-31.11%
HK:9995RemeGen Co. Ltd. Class H64.85-28.00-30.16%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H15.26-11.44-42.85%
HK:2696Shanghai Henlius Biotech, Inc. Class H49.06-20.04-29.00%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts